1
|
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
|
JAMA
|
1999
|
7.30
|
2
|
Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.
|
N Engl J Med
|
1992
|
3.54
|
3
|
A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity.
|
J Endocrinol
|
1977
|
3.03
|
4
|
The pharmacology and clinical uses of tamoxifen.
|
Pharmacol Ther
|
1984
|
3.02
|
5
|
Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
|
J Natl Cancer Inst
|
1998
|
2.88
|
6
|
A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy.
|
Recent Results Cancer Res
|
1993
|
2.65
|
7
|
Basic guide to the mechanisms of antiestrogen action.
|
Pharmacol Rev
|
1998
|
2.50
|
8
|
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
|
Breast Cancer Res Treat
|
2001
|
2.26
|
9
|
Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor.
|
J Natl Cancer Inst
|
1992
|
2.19
|
10
|
MCF-7: the first hormone-responsive breast cancer cell line.
|
Cancer Res
|
1997
|
2.12
|
11
|
Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient.
|
Drug Metab Dispos
|
1991
|
2.04
|
12
|
Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer.
|
J Natl Cancer Inst
|
1990
|
1.97
|
13
|
Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration.
|
Cancer Res
|
1988
|
1.80
|
14
|
Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
|
Cancer Res
|
1996
|
1.79
|
15
|
Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture.
|
Cancer Res
|
1990
|
1.78
|
16
|
Biochemical pharmacology of antiestrogen action.
|
Pharmacol Rev
|
1984
|
1.74
|
17
|
Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
|
Clin Cancer Res
|
2000
|
1.73
|
18
|
Antiestrogenic and antitumor properties of tamoxifen in laboratory animals.
|
Cancer Treat Rep
|
1976
|
1.63
|
19
|
Effects of tamoxifen on cardiovascular risk factors in postmenopausal women.
|
Ann Intern Med
|
1991
|
1.55
|
20
|
Effect of cadmium on estrogen receptor levels and estrogen-induced responses in human breast cancer cells.
|
J Biol Chem
|
1994
|
1.53
|
21
|
Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.
|
Cancer Res
|
1987
|
1.52
|
22
|
Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata.
|
Eur J Cancer
|
1976
|
1.50
|
23
|
Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance.
|
Breast Cancer Res Treat
|
1982
|
1.48
|
24
|
Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse.
|
Cancer Res
|
1988
|
1.44
|
25
|
Tamoxifen and contralateral breast cancer.
|
J Am Coll Surg
|
1999
|
1.41
|
26
|
An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol.
|
Mol Cell Endocrinol
|
1992
|
1.39
|
27
|
Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture.
|
Eur J Cancer Clin Oncol
|
1987
|
1.38
|
28
|
Pharmacology of tamoxifen in laboratory animals.
|
Cancer Treat Rep
|
1981
|
1.37
|
29
|
A risk-benefit assessment of tamoxifen therapy.
|
Drug Saf
|
1993
|
1.34
|
30
|
Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal.
|
J Steroid Biochem Mol Biol
|
2005
|
1.31
|
31
|
Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years.
|
Breast Cancer Res Treat
|
1988
|
1.29
|
32
|
Tamoxifen as an anti-tumour agent: effect on oestrogen binding.
|
J Endocrinol
|
1976
|
1.27
|
33
|
Evaluation of the antitumour activity of the non-steroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model.
|
Eur J Cancer
|
1980
|
1.27
|
34
|
An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein.
|
Cancer Res
|
1995
|
1.23
|
35
|
High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects.
|
J Clin Oncol
|
1989
|
1.21
|
36
|
Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen.
|
J Steroid Biochem
|
1988
|
1.19
|
37
|
Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen.
|
Cancer Res
|
1988
|
1.19
|
38
|
Studies on the mechanism of action of the nonsteroidal antioestrogen tamoxifen (I.C.I. 46,474) in the rat.
|
Mol Cell Endocrinol
|
1977
|
1.18
|
39
|
Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens.
|
Cancer Res
|
1989
|
1.17
|
40
|
Evidence for the metabolic activation of non-steroidal antioestrogens: a study of structure-activity relationships.
|
Br J Pharmacol
|
1980
|
1.16
|
41
|
Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue.
|
Cancer Lett
|
1995
|
1.16
|
42
|
Structure-activity relationships of estrogens.
|
Environ Health Perspect
|
1985
|
1.15
|
43
|
Stimulation of breast cancer cells in vitro by the environmental estrogen enterolactone and the phytoestrogen equol.
|
Breast Cancer Res Treat
|
1987
|
1.13
|
44
|
Tamoxifen as an anti-tumour agent: oestrogen binding as a predictive test for tumour response.
|
J Endocrinol
|
1976
|
1.12
|
45
|
Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation.
|
Br J Cancer
|
1996
|
1.12
|
46
|
Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor.
|
Eur J Cancer
|
1975
|
1.06
|
47
|
Reliability of steroid hormone receptor assays: an international study.
|
Eur J Cancer Clin Oncol
|
1983
|
1.06
|
48
|
Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro.
|
Mol Pharmacol
|
1990
|
1.05
|
49
|
High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine.
|
J Natl Cancer Inst
|
1992
|
1.04
|
50
|
Binding of [3H]tamoxifen in rat uterine cytosols: a comparison of swinging bucket and vertical tube rotor sucrose density gradient analysis.
|
Mol Cell Endocrinol
|
1977
|
1.03
|
51
|
Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines.
|
Br J Cancer
|
2000
|
1.03
|
52
|
Species-specific pharmacology of antiestrogens: role of metabolism.
|
Fed Proc
|
1987
|
1.02
|
53
|
Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha.
|
Clin Cancer Res
|
2001
|
1.02
|
54
|
Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer.
|
Cancer Res
|
1987
|
1.02
|
55
|
Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions.
|
Cancer Res
|
1990
|
1.01
|
56
|
Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer.
|
Oncogene
|
2012
|
1.01
|
57
|
A realistic clinical perspective of tamoxifen and endometrial carcinogenesis.
|
Eur J Cancer
|
1996
|
1.00
|
58
|
Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer.
|
Eur J Cancer
|
1990
|
0.99
|
59
|
Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells.
|
Br J Pharmacol
|
2013
|
0.99
|
60
|
The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain.
|
Breast Cancer Res Treat
|
1994
|
0.98
|
61
|
Transfection of human estrogen receptor (ER) cDNA into ER-negative mammalian cell lines.
|
J Steroid Biochem Mol Biol
|
1994
|
0.98
|
62
|
The antitumour activity of tamoxifen and monohydroxytamoxifen: a comparative study in the rat [proceedings].
|
Br J Pharmacol
|
1978
|
0.97
|
63
|
Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice.
|
Breast Cancer Res Treat
|
1994
|
0.96
|
64
|
Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III.
|
Cancer Res
|
1987
|
0.96
|
65
|
Estrogenic activity of phenol red.
|
Mol Cell Endocrinol
|
1988
|
0.96
|
66
|
Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor.
|
J Steroid Biochem Mol Biol
|
1997
|
0.96
|
67
|
Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice.
|
Clin Cancer Res
|
2000
|
0.95
|
68
|
Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow.
|
J Natl Cancer Inst
|
1998
|
0.95
|
69
|
Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018.
|
Endocrinology
|
1983
|
0.95
|
70
|
Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro.
|
Mol Pharmacol
|
1984
|
0.95
|
71
|
Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer.
|
Cancer Res
|
1983
|
0.94
|
72
|
A novel 80 kDa human estrogen receptor containing a duplication of exons 6 and 7.
|
Nucleic Acids Res
|
1996
|
0.94
|
73
|
Effects of low dose tamoxifen on normal breast tissue from premenopausal women.
|
Eur J Cancer
|
2003
|
0.94
|
74
|
Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro.
|
Cancer Res
|
1989
|
0.94
|
75
|
The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor.
|
Cancer Res
|
1998
|
0.93
|
76
|
Differences between estrogen- and antiestrogen-estrogen receptor complexes from human breast tumors identified with an antibody raised against the estrogen receptor.
|
Cancer Res
|
1984
|
0.93
|
77
|
Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites.
|
J Natl Cancer Inst
|
1993
|
0.93
|
78
|
How safe is tamoxifen?
|
BMJ
|
1993
|
0.93
|
79
|
Protein kinase C alpha expression is inversely related to ER status in endometrial carcinoma: possible role in AP-1-mediated proliferation of ER-negative endometrial cancer.
|
Gynecol Oncol
|
2001
|
0.92
|
80
|
Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts.
|
Eur J Cancer Clin Oncol
|
1989
|
0.91
|
81
|
The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor.
|
Br J Cancer
|
1998
|
0.91
|
82
|
Decrease in estradiol-stimulated progesterone receptor production in MCF-7 cells by epidermal growth factor and possible clinical implication for paracrine-regulated breast cancer growth.
|
Cancer Res
|
1989
|
0.90
|
83
|
Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
|
Cancer Res
|
2000
|
0.90
|
84
|
A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood.
|
Clin Cancer Res
|
1997
|
0.90
|
85
|
Estrogenic effects of phenolphthalein on human breast cancer cells in vitro.
|
Breast Cancer Res Treat
|
1987
|
0.90
|
86
|
Enhanced growth of an estrogen receptor-negative endometrial adenocarcinoma by estradiol in athymic mice.
|
Cancer Res
|
1989
|
0.89
|
87
|
Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells.
|
Gynecol Oncol
|
2002
|
0.89
|
88
|
Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse.
|
Cancer Res
|
1989
|
0.89
|
89
|
Estrogen-stimulated prolactin synthesis in vitro. Classification of agonist, partial agonist, and antagonist actions based on structure.
|
Mol Pharmacol
|
1984
|
0.89
|
90
|
Gynecologic effects of tamoxifen and the association with endometrial carcinoma.
|
Int J Gynaecol Obstet
|
1995
|
0.89
|
91
|
Targeting oestrogen to kill the cancer but not the patient.
|
Br J Cancer
|
2004
|
0.89
|
92
|
Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism.
|
Br J Cancer
|
1993
|
0.88
|
93
|
An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro.
|
J Biol Chem
|
1983
|
0.88
|
94
|
Designer estrogens.
|
Sci Am
|
1998
|
0.88
|
95
|
Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex.
|
Cancer Res
|
2001
|
0.88
|
96
|
Nonsteroidal antiestrogens: their biological effects and potential mechanisms of action.
|
J Toxicol Environ Health
|
1978
|
0.87
|
97
|
Tamoxifen and endometrial cancer.
|
Lancet
|
1988
|
0.87
|
98
|
Short- and long-term estrogen deprivation of T47D human breast cancer cells in culture.
|
Eur J Cancer Clin Oncol
|
1989
|
0.87
|
99
|
Control of the estrogen-like actions of the tamoxifen-estrogen receptor complex by the surface amino acid at position 351.
|
J Steroid Biochem Mol Biol
|
2001
|
0.87
|
100
|
Effects of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen.
|
Cancer Res
|
1989
|
0.87
|
101
|
Direct and reversible inhibition of estradiol-stimulated prolactin synthesis by antiestrogens in vitro.
|
J Biol Chem
|
1983
|
0.86
|
102
|
Molecular mechanisms of resistance to tamoxifen therapy in breast cancer.
|
Arch Surg
|
1993
|
0.86
|
103
|
Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
|
Br J Cancer
|
1998
|
0.86
|
104
|
Oestradiol stimulates growth of oestrogen receptor-negative MDA-MB-231 breast cancer cells in immunodeficient mice by reducing cell loss.
|
Eur J Cancer
|
1994
|
0.86
|
105
|
Possible mechanisms in the emergence of tamoxifen-resistant breast cancer.
|
Anticancer Drugs
|
1995
|
0.86
|
106
|
Tamoxifen as an anti-tumour agent: role of oestradiol and prolactin.
|
J Endocrinol
|
1976
|
0.86
|
107
|
Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice.
|
Cancer Res
|
1990
|
0.86
|
108
|
Modulation of rat uterine steroid hormone receptors by estrogen and antiestrogen.
|
Endocrinology
|
1980
|
0.86
|
109
|
Oestrogenic and antioestrogenic actions in a series of triphenylbut-1-enes: modulation of prolactin synthesis in vitro.
|
Br J Pharmacol
|
1986
|
0.85
|
110
|
Selective oestrogen receptor modulation: molecular pharmacology for the millennium.
|
Eur J Cancer
|
1999
|
0.85
|
111
|
Interaction of [3H] estradiol - and [3H] monohydroxytamoxifen-estrogen receptor complexes with a monoclonal antibody.
|
Breast Cancer Res Treat
|
1983
|
0.85
|
112
|
A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog.
|
Mol Endocrinol
|
1995
|
0.85
|
113
|
Tamoxifen: the herald of a new era of preventive therapeutics.
|
J Natl Cancer Inst
|
1997
|
0.85
|
114
|
Metabolism of steroid-modifying anticancer agents.
|
Pharmacol Ther
|
1988
|
0.85
|
115
|
Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts.
|
Clin Cancer Res
|
2001
|
0.85
|
116
|
Considerations into the mechanism of estrogen-stimulated uterine prostaglandin synthesis.
|
Prostaglandins
|
1976
|
0.84
|
117
|
Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation.
|
Cancer Res
|
1992
|
0.84
|
118
|
Geometric isomers of substituted triphenylethylenes and antiestrogen action.
|
Endocrinology
|
1981
|
0.84
|
119
|
Clinical potential of new antiestrogens.
|
J Clin Oncol
|
1997
|
0.84
|
120
|
The effect of estrogen and progesterone on uterine prostaglandin biosynthesis in the ovariectomized rat.
|
Biol Reprod
|
1975
|
0.84
|
121
|
Molecular classification of selective oestrogen receptor modulators on the basis of gene expression profiles of breast cancer cells expressing oestrogen receptor alpha.
|
Br J Cancer
|
2002
|
0.84
|
122
|
In vitro estrogenic actions in rat and human cells of hydroxylated derivatives of D16726 (zindoxifene), an agent with known antimammary cancer activity in vivo.
|
Cancer Res
|
1988
|
0.84
|
123
|
Comparative antioestrogen action in experimental breast cancer.
|
Adv Exp Med Biol
|
1981
|
0.84
|
124
|
William L. McGuire Memorial Symposium. Drug resistance to tamoxifen during breast cancer therapy.
|
Breast Cancer Res Treat
|
1993
|
0.84
|
125
|
Metabolism of tamoxifen and its uterotrophic activity.
|
Biochem Pharmacol
|
1985
|
0.84
|
126
|
The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer.
|
J Steroid Biochem Mol Biol
|
1997
|
0.84
|
127
|
Growth stimulation and differential regulation of transforming growth factor-beta 1 (TGF beta 1), TGF beta 2, and TGF beta 3 messenger RNA levels by norethindrone in MCF-7 human breast cancer cells.
|
Mol Endocrinol
|
1991
|
0.84
|
128
|
Paradoxical regulation of estrogen-dependent growth factor gene expression in estrogen receptor (ER)-negative human breast cancer cells stably expressing ER.
|
Cancer Lett
|
1994
|
0.83
|
129
|
Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation.
|
Br J Urol
|
1988
|
0.83
|
130
|
Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
|
Clin Cancer Res
|
1999
|
0.83
|
131
|
Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER.
|
Mol Endocrinol
|
1992
|
0.83
|
132
|
Effect of non-steroidal anti-oestrogens on the concentration of rat uterine progesterone receptors.
|
J Endocrinol
|
1978
|
0.83
|
133
|
Estrogenic actions of RU486 in hormone-responsive MCF-7 human breast cancer cells.
|
Endocrinology
|
1993
|
0.83
|
134
|
In vitro study of the effect of raloxifene on lipid metabolism compared with tamoxifen.
|
Eur J Endocrinol
|
2000
|
0.83
|
135
|
Selective oestrogen receptor modulation: molecular pharmacology for the millennium.
|
Eur J Cancer
|
1999
|
0.82
|
136
|
Contrasting ability of antiestrogens to inhibit MCF-7 growth stimulated by estradiol or epidermal growth factor.
|
Eur J Cancer Clin Oncol
|
1989
|
0.82
|
137
|
Rat uterine growth and induction of progesterone receptor without estrogen receptor translocation.
|
Endocrinology
|
1985
|
0.82
|
138
|
Laboratory models of breast cancer to aid the elucidation of antiestrogen action.
|
J Lab Clin Med
|
1987
|
0.82
|
139
|
Reversible control of oestradiol-stimulated growth of MCF-7 tumours by tamoxifen in the athymic mouse.
|
Br J Cancer
|
1991
|
0.82
|
140
|
Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications.
|
Breast Cancer Res Treat
|
1983
|
0.82
|
141
|
Comparison of the effects of tamoxifen and toremifene on liver and kidney tumor promotion in female rats.
|
Carcinogenesis
|
1995
|
0.82
|
142
|
Regulation of the levels of three transforming growth factor beta mRNAs by estrogen and their effects on the proliferation of human breast cancer cells.
|
Mol Cell Endocrinol
|
1993
|
0.82
|
143
|
Prophylactic tamoxifen.
|
Lancet
|
1986
|
0.82
|
144
|
Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice.
|
Clin Cancer Res
|
2000
|
0.82
|
145
|
Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
|
J Clin Oncol
|
1987
|
0.81
|
146
|
4-Hydroxytamoxifen, an active metabolite of tamoxifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiated in vitro.
|
Breast Cancer Res Treat
|
1994
|
0.81
|
147
|
Effects of tamoxifen in relation to breast cancer.
|
Br Med J
|
1977
|
0.81
|
148
|
Targeted anti-estrogens to treat and prevent diseases in women.
|
Mol Med Today
|
1996
|
0.81
|
149
|
Dose-related effects of non-steroidal antioestrogens nad oestrogens on the measurement of cytoplasmic oestrogen receptors in the rat and mouse uterus.
|
J Endocrinol
|
1978
|
0.81
|
150
|
How is tamoxifen's action subverted?
|
J Natl Cancer Inst
|
2000
|
0.81
|
151
|
Effects of the new selective estrogen receptor modulator LY353381.HCl (Arzoxifene) on human endometrial cancer growth in athymic mice.
|
Clin Cancer Res
|
2001
|
0.81
|
152
|
Novel agents to modulate oestrogen action.
|
Br Med Bull
|
2000
|
0.81
|
153
|
Estrogen receptor distribution in enucleated breast cancer cell lines.
|
Endocrinology
|
1988
|
0.81
|
154
|
EGF activates highly selective estrogen-responsive reporter plasmids by an ER-independent pathway.
|
Mol Cell Endocrinol
|
2000
|
0.81
|
155
|
The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor.
|
Cancer Res
|
1999
|
0.81
|
156
|
Raloxifene as a multifunctional medicine? Current trials will show whether it is effective in both osteoporosis and breast cancer.
|
BMJ
|
1999
|
0.81
|
157
|
Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy.
|
Eur J Cancer
|
1993
|
0.81
|
158
|
What do we know and what don't we know about tamoxifen in the human uterus.
|
Breast Cancer Res Treat
|
1994
|
0.80
|
159
|
Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing.
|
J Natl Cancer Inst
|
2001
|
0.80
|
160
|
Phase II enzyme expression in rat liver in response to the antiestrogen tamoxifen.
|
Cancer Res
|
1996
|
0.80
|
161
|
Effects of tamoxifen administration on the expression of xenobiotic metabolizing enzymes in rat liver.
|
Cancer Res
|
1995
|
0.80
|
162
|
Determination of tamoxifen and metabolites in human serum by high-performance liquid chromatography with post-column fluorescence activation.
|
J Chromatogr
|
1983
|
0.80
|
163
|
Subcellular compartmentalization of MCF-7 estrogen receptor synthesis and degradation.
|
Mol Cell Endocrinol
|
1993
|
0.80
|
164
|
Anti-oestrogenic activity in compounds related to ethamoxytriphetol (MER 25), clomiphene and MRL 37.
|
Br J Pharmacol
|
1973
|
0.80
|
165
|
Differences in the rate of oestrogen-induced apoptosis in breast cancer by oestradiol and the triphenylethylene bisphenol.
|
Br J Pharmacol
|
2014
|
0.80
|
166
|
Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus.
|
Cancer Res
|
1997
|
0.80
|
167
|
Importance of the alkylaminoethoxy side-chain for the estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the immature rat uterus.
|
Mol Cell Endocrinol
|
1982
|
0.80
|
168
|
Nonisomerizable analogues of (Z)- and (E)-4-hydroxytamoxifen. Synthesis and endocrinological properties of substituted diphenylbenzocycloheptenes.
|
J Med Chem
|
1988
|
0.80
|
169
|
Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
|
Mol Pharmacol
|
1991
|
0.80
|
170
|
Steroid hormone receptors in adenocarcinoma of the endometrium.
|
Gynecol Oncol
|
1980
|
0.80
|
171
|
Opposing biological actions of antiestrogens in vitro and in vivo: induction of progesterone receptor in the rat and mouse uterus.
|
Endocrinology
|
1985
|
0.80
|
172
|
Methylation of CpG island is not a ubiquitous mechanism for the loss of oestrogen receptor in breast cancer cells.
|
Br J Cancer
|
1998
|
0.80
|
173
|
Effect of oestradiol benzoate, tamoxifen and monohydroxytamoxifen on immature rat uterine progesterone receptor synthesis and endometrial cell division.
|
J Steroid Biochem
|
1979
|
0.80
|
174
|
Tamoxifen and tumorigenicity: a predictable concern.
|
J Natl Cancer Inst
|
1995
|
0.79
|
175
|
A pilot study of the effects of short-term tamoxifen therapy on Ki-67 labelling index in women with primary breast cancer.
|
Int J Oncol
|
2000
|
0.79
|
176
|
The effect of reported prostaglandin synthetase inhibitors on estradiol-stimulated uterine prostaglandin biosynthesis in vivo in the ovariectomized rat.
|
Prostaglandins
|
1976
|
0.79
|
177
|
Estrogen receptor-mediated direct and indirect antitumor effects of tamoxifen.
|
J Natl Cancer Inst
|
1990
|
0.79
|
178
|
Differential antiestrogen action in the immature rat uterus: a comparison of hydroxylated antiestrogens with high affinity for the estrogen receptor.
|
J Steroid Biochem
|
1983
|
0.79
|
179
|
Growth factor regulation by tamoxifen is demonstrated in patients with breast cancer.
|
Cancer
|
1993
|
0.79
|
180
|
Tamoxifen: too much of a good thing?
|
J Clin Oncol
|
1999
|
0.79
|
181
|
Cloning and characterization of a 77-kDa oestrogen receptor isolated from a human breast cancer cell line.
|
Br J Cancer
|
1997
|
0.79
|
182
|
Tamoxifen in liver disease: potential exacerbation of hepatic dysfunction.
|
Ann Oncol
|
1998
|
0.79
|
183
|
Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism.
|
J Hepatol
|
1995
|
0.79
|
184
|
The binding of [3H]-oestradiol-17 beta in the immature rat uterus during the sequential administration of non-steroidal anti-oestrogens.
|
Br J Pharmacol
|
1979
|
0.79
|
185
|
The decreased influence of overall treatment time on the response of human breast tumor xenografts following prolongation of the potential doubling time (Tpot).
|
Int J Radiat Oncol Biol Phys
|
1995
|
0.79
|
186
|
The effect of tamoxifen and two of its non-isomerizable fixed-ring analogs on multistage rat hepatocarcinogenesis.
|
Carcinogenesis
|
1996
|
0.79
|
187
|
Mutations of the estrogen receptor in endometrial carcinoma: evidence of an association with high tumor grade.
|
Gynecol Oncol
|
1996
|
0.79
|
188
|
Risk factors and the prevention of breast cancer with tamoxifen.
|
Cancer Surv
|
1993
|
0.79
|
189
|
The paracrine stimulation of MCF-7 cells by MDA-MB-231 cells: possible role in antiestrogen failure.
|
Eur J Cancer Clin Oncol
|
1989
|
0.78
|
190
|
Preclinical studies with toremifene as an antitumor agent.
|
Breast Cancer Res Treat
|
1990
|
0.78
|
191
|
Long-term adjuvant tamoxifen study: clinical update.
|
Breast Cancer Res Treat
|
1987
|
0.78
|
192
|
Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells.
|
Cancer Lett
|
1998
|
0.78
|
193
|
Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study.
|
Breast Cancer Res Treat
|
1984
|
0.78
|
194
|
Pure antiestrogens as a new therapy for breast cancer.
|
Oncol Res
|
1997
|
0.78
|
195
|
High affinity binding of anti-oestrogen to the chick liver nuclear oestrogen receptor.
|
Biochem J
|
1982
|
0.78
|
196
|
Effects of angiogenesis inhibitor TNP-470 on tamoxifen-stimulated MCF-7 breast tumors in nude mice.
|
Cancer Lett
|
2000
|
0.78
|
197
|
Tamoxifen-induced increase in the potential doubling time of MCF-7 xenografts as determined by bromodeoxyuridine labeling and flow cytometry.
|
Cancer Res
|
1993
|
0.78
|
198
|
The mode of action of the antitumour agent GP 48,989 in the rat.
|
Eur J Cancer
|
1979
|
0.78
|
199
|
Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-alpha 2.
|
Breast Cancer Res Treat
|
1990
|
0.78
|
200
|
Should adjuvant tamoxifen therapy be stopped at 5 years?
|
Cancer J Sci Am
|
2006
|
0.78
|
201
|
Targeted antiestrogens for the prevention of breast cancer.
|
Oncol Res
|
1999
|
0.78
|
202
|
Subcellular effects of monohydroxytamoxifen in the rat uterus: steroid receptors and mitosis.
|
J Endocrinol
|
1980
|
0.78
|
203
|
Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer.
|
Gynecol Oncol
|
1992
|
0.78
|
204
|
The biological action of cDNAs from mutated estrogen receptors transfected into breast cancer cells.
|
Cancer Lett
|
1995
|
0.78
|
205
|
A comparative study of electrophoretic mobilities of [3H]-estradiol and monohydroxytamoxifen binding components in the cytosols of human breast carcinomas and sera of healthy adult females.
|
Eur J Cancer Clin Oncol
|
1983
|
0.78
|
206
|
Possible mechanisms for the agonist actions of tamoxifen and the antagonist actions of MER-25 (ethamoxytriphetol) in the mouse uterus.
|
Biochem Pharmacol
|
1985
|
0.78
|
207
|
Tamoxifen to raloxifene and beyond.
|
Semin Oncol
|
2001
|
0.78
|
208
|
Hormonal therapy for breast cancer. An update.
|
Hematol Oncol Clin North Am
|
1999
|
0.78
|
209
|
Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine-activated killer cells.
|
J Immunother (1991)
|
1992
|
0.77
|
210
|
Prolonged antioestrogenic activity of ICI 46, 474 in the ovariectomized mouse.
|
J Reprod Fertil
|
1975
|
0.77
|
211
|
Inhibition of cell division and stimulation of progesterone receptor synthesis in rat oestrogen target tissues by non-steroidal antioestrogens.
|
Adv Exp Med Biol
|
1979
|
0.77
|
212
|
Tamoxifen inhibits lipoprotein activity: in vivo and in vitro studies.
|
Horm Res
|
2000
|
0.77
|
213
|
Chemotherapy is antihormonal therapy--how much proof do oncologists need?
|
Eur J Cancer
|
1998
|
0.77
|
214
|
Antiestrogen stimulated human endometrial cancer growth: laboratory and clinical considerations.
|
J Steroid Biochem Mol Biol
|
1998
|
0.77
|
215
|
Contrasting subcellular responses to monohydroxytamoxifen and oestradiol benzoate in the immature rat uterus [proceedings].
|
Br J Pharmacol
|
1978
|
0.77
|
216
|
Identification of a new metabolite of tamoxifen in patient serum during breast cancer therapy.
|
Biochem Pharmacol
|
1983
|
0.77
|
217
|
Reversal of the antitumor effects of tamoxifen by progesterone in the 7,12-dimethylbenzanthracene-induced rat mammary carcinoma model.
|
Cancer Res
|
1987
|
0.77
|
218
|
Sensitivity and insensitivity of breast cancer to tamoxifen.
|
J Steroid Biochem Mol Biol
|
1990
|
0.77
|
219
|
Nomegestrol acetate, a clinically useful 19-norprogesterone derivative which lacks estrogenic activity.
|
J Steroid Biochem Mol Biol
|
1995
|
0.77
|
220
|
Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats.
|
Cancer Res
|
1994
|
0.77
|
221
|
The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogens.
|
J Mammary Gland Biol Neoplasia
|
1999
|
0.77
|
222
|
Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model.
|
Eur J Cancer Clin Oncol
|
1988
|
0.77
|
223
|
Control of experimental breast cancer by antioestrogenic therapies [proceedings].
|
Br J Clin Pharmacol
|
1979
|
0.77
|
224
|
A comparison, at the cellular and subcellular levels, of the effects of tamoxifen and oestradiol benzoate on the immature rat uterus [proceedings].
|
Br J Pharmacol
|
1978
|
0.77
|
225
|
Tamoxifen and endometrial cancer.
|
Lancet
|
1989
|
0.76
|
226
|
Determination of estrogen receptor in breast cancer using monoclonal antibody technology: results of a multicenter study in the United States.
|
Cancer Res
|
1986
|
0.76
|
227
|
Tamoxifen to prevent breast cancer.
|
Adv Surg
|
2000
|
0.76
|
228
|
Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells.
|
J Steroid Biochem Mol Biol
|
2001
|
0.76
|
229
|
Inhibition of oestrogen-stimulated prolactin release by anti-oestrogens.
|
J Endocrinol
|
1975
|
0.76
|
230
|
Tamoxifen for the prevention of breast cancer in the high-risk woman.
|
Ann Surg Oncol
|
2000
|
0.76
|
231
|
Risks and benefits of tamoxifen therapy.
|
Oncology (Williston Park)
|
1997
|
0.76
|
232
|
Anti-oestrogen action in experimental breast cancer.
|
Recent Results Cancer Res
|
1980
|
0.76
|
233
|
Binding of [3H]monohydroxytamoxifen by immature rat tissues in vivo.
|
Endocrinology
|
1982
|
0.76
|
234
|
Inhibition of oestradiol binding to mouse uterine and vaginal oestrogen receptors by triphenylethylenes.
|
J Endocrinol
|
1975
|
0.76
|
235
|
Reduced antioestrogenic activity in derivatives of tamoxifen unable to undergo metabolic p-hydroxylation [proceedings].
|
Br J Pharmacol
|
1980
|
0.75
|
236
|
Nuclear [3H]4-hydroxytamoxifen (4-OHTAM)- and [3H]estradiol (E2)-estrogen receptor complexes in the MCF-7 breast cancer and GH3 pituitary tumor cell lines.
|
Mol Cell Endocrinol
|
1984
|
0.75
|
237
|
A therapeutic withdrawal can make a strategic advance.
|
Ann Oncol
|
1992
|
0.75
|
238
|
Modulation of nuclear oestrogen receptor levels by oestrogen and antioestrogen [proceedings].
|
Br J Pharmacol
|
1980
|
0.75
|
239
|
Structural derivatives of tamoxifen and oestradiol 3-methyl ether as potential alkylating antioestrogens.
|
Eur J Cancer
|
1981
|
0.75
|
240
|
Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats.
|
Carcinogenesis
|
1996
|
0.75
|
241
|
Safety of tamoxifen.
|
BMJ
|
1994
|
0.75
|
242
|
Oestrogenic, anti-oestrogenic and fertility effects of some triphenylethanes and triphenylethylenes related to ethamoxytriphetol (MER 25).
|
Br J Pharmacol
|
1976
|
0.75
|
243
|
The inhibition of prolactin synthesis in GH3 rat pituitary tumor cells by monohydroxytamoxifen is associated with changes in the properties of the estrogen receptor.
|
J Steroid Biochem
|
1984
|
0.75
|
244
|
Antiestrogens and the reduction in circulating cholesterol.
|
J Clin Oncol
|
1996
|
0.75
|
245
|
Antioestrogenic derivatives of nafoxidine stimulate progesterone receptor synthesis in vivo [proceedings].
|
Br J Pharmacol
|
1980
|
0.75
|
246
|
Control of experimental breast cancer by antioestrogenic therapies [proceedings].
|
Br J Pharmacol
|
1979
|
0.75
|
247
|
Targeting antihormone resistance in breast cancer: a simple solution.
|
Ann Oncol
|
2003
|
0.75
|
248
|
After the menopause: tamoxifen and other new prevention maintenance therapies.
|
J Womens Health
|
1997
|
0.75
|
249
|
Raloxifene for the treatment and prevention of breast cancer?
|
Expert Rev Anticancer Ther
|
2001
|
0.75
|
250
|
Inhibition of oestradiol binding to oestrogen receptor proteins by a methyl-substituted analogue of tamoxifen.
|
J Endocrinol
|
1976
|
0.75
|
251
|
A molecular strategy to control tamoxifen resistant breast cancer.
|
Cancer Surv
|
1992
|
0.75
|
252
|
Tamoxifen prophylaxis.
|
Lancet
|
1986
|
0.75
|
253
|
The forgotten group at risk for breast cancer.
|
J Clin Oncol
|
1990
|
0.75
|
254
|
Binding of [3H] monohydroxytamoxifen in ovarian carcinoma.
|
Br J Obstet Gynaecol
|
1983
|
0.75
|
255
|
Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines.
|
Br J Cancer
|
2016
|
0.75
|
256
|
Activity of the antioestrogen trioxifene against N-Nitrosomethylurea-induced rat mammary carcinomas.
|
Eur J Cancer Clin Oncol
|
1981
|
0.75
|
257
|
Antiestrogen therapy for breast cancer: current strategies and future prospects.
|
Cancer Treat Res
|
1988
|
0.75
|
258
|
Effect of chronic administration of mestranol, tamoxifen, and toremifene on hepatic ploidy in rats.
|
Toxicol Sci
|
1998
|
0.75
|
259
|
Hormonal treatment of advanced breast cancer.
|
Surg Oncol Clin N Am
|
1995
|
0.75
|
260
|
An analysis of tamoxifen-stimulated human carcinomas for mutations in the AF-2 region of the estrogen receptor.
|
J Steroid Biochem Mol Biol
|
1996
|
0.75
|
261
|
Human recombinant interferon-beta SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse.
|
Breast Cancer Res Treat
|
1993
|
0.75
|
262
|
Detection of the 8 S oestrogen-binding component in human uterine endometrium during the menstrual cycle.
|
J Endocrinol
|
1975
|
0.75
|
263
|
Chemoprevention of breast cancer.
|
Cancer Treat Res
|
2001
|
0.75
|
264
|
The effects of intermittent progesterone upon tamoxifen inhibition of tumor growth in the 7,12-dimethylbenzanthracene rat mammary tumor model.
|
Breast Cancer Res Treat
|
1993
|
0.75
|
265
|
Antiestrogenic effect of trifluoperazine in mice.
|
Biochem Pharmacol
|
1985
|
0.75
|
266
|
Health and safety inspections.
|
Lancet
|
1977
|
0.75
|
267
|
[Effect of tamoxifen on estrogen-stimulated growth of MCF-7 tumors in athymic mice: preliminary report].
|
Nihon Geka Gakkai Zasshi
|
1990
|
0.75
|
268
|
Current controversies in breast cancer management.
|
Curr Probl Surg
|
1999
|
0.75
|
269
|
Binding of [3H] monohydroxytamoxifen in human breast carcinoma cytosols.
|
Eur J Cancer
|
1981
|
0.75
|
270
|
Design of an ideal hormone replacement therapy for women.
|
Mol Carcinog
|
1996
|
0.75
|
271
|
Steroid and prostaglandin relations during the menstrual cycle.
|
Obstet Gynecol
|
1977
|
0.75
|
272
|
Active immunization to luteinizing hormone releasing hormone to inhibit the induction of mammary tumors in the rat.
|
Life Sci
|
1988
|
0.75
|
273
|
A model to describe how a point mutation of the estrogen receptor alters the structure-function relationship of antiestrogens.
|
Breast Cancer Res Treat
|
1993
|
0.75
|
274
|
Laboratory models of breast and endometrial cancer to develop strategies for antiestrogen therapy.
|
Breast Cancer
|
1998
|
0.75
|
275
|
Long-term tamoxifen therapy for breast cancer.
|
Important Adv Oncol
|
1989
|
0.75
|
276
|
Effects of antiestrogens on the induction of vitellogenin and its mRNA in Xenopus laevis.
|
J Steroid Biochem
|
1986
|
0.75
|
277
|
Structural components necessary for the antiestrogenic activity of tamoxifen.
|
J Steroid Biochem
|
1989
|
0.75
|
278
|
The evolving role of endocrine therapy for treatment and prevention of breast cancer.
|
Cancer Chemother Biol Response Modif
|
2001
|
0.75
|
279
|
An immobilized antiestrogen binds a specific uterine protein in addition to estrogen receptor proteins.
|
Mol Cell Endocrinol
|
1984
|
0.75
|
280
|
Targeted antiestrogens.
|
Prog Clin Biol Res
|
1997
|
0.75
|
281
|
Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats.
|
Breast Cancer Res Treat
|
1994
|
0.75
|
282
|
Tamoxifen-failed male breast cancer with a high level of circulating estrogen: report of a case.
|
Surg Today
|
2001
|
0.75
|
283
|
Characterization of a point mutation in the hormone binding domain of the estrogen receptor from an breast tumor.
|
Int J Oncol
|
1998
|
0.75
|
284
|
Is it time to develop an optimal endocrine therapy for premenopausal patients with axillary node positive and negative breast cancer?
|
Semin Surg Oncol
|
1997
|
0.75
|
285
|
Tamoxifen and endometrial cancer: from experiment to patient.
|
Recent Results Cancer Res
|
1996
|
0.75
|
286
|
Meeting report: long-term antihormonal therapy for breast cancer.
|
Eur J Cancer
|
1991
|
0.75
|
287
|
Antiestrogen therapy for breast cancer: current strategies and potential causes for therapeutic failure.
|
Cancer Treat Res
|
1991
|
0.75
|
288
|
Adjuvant antiestrogen therapy for breast cancer. Past, present, and future.
|
Surg Clin North Am
|
1990
|
0.75
|
289
|
Effect of submandibular gland removal on carcinogen induced rat mammary tumors.
|
Eur J Cancer Clin Oncol
|
1987
|
0.75
|
290
|
The duration of adjuvant tamoxifen therapy.
|
Cancer Treat Res
|
1998
|
0.75
|
291
|
Antiestrogens: the past and the future.
|
Zentralbl Gynakol
|
2002
|
0.75
|
292
|
Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer.
|
Endocr Relat Cancer
|
1999
|
0.75
|
293
|
Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death.
|
Br J Cancer
|
2016
|
0.75
|
294
|
Legislation and hospitals.
|
Occup Health (Lond)
|
1971
|
0.75
|
295
|
The biological significance of the interaction of estrogen agonists and antagonists with the estrogen receptor.
|
Receptor
|
1993
|
0.75
|
296
|
New strategies for the treatment of breast cancer.
|
Breast Cancer
|
2001
|
0.75
|
297
|
Structure-activity relationships for triphenylethylene antiestrogens on hepatic phase-I and phase-II enzyme expression.
|
Biochem Pharmacol
|
1998
|
0.75
|
298
|
Relation of steroids and prostaglandin at vaginal delivery and cesarean section.
|
Obstet Gynecol
|
1975
|
0.75
|